|
**Overview**: **FT3 FT4 Profile****Introduction**: The FT3 FT4 Profile is a diagnostic tool designed to assess free thyroid hormones using serum samples. Associated with conditions like hypothyroidism and hyperthyroidism, these disorders present with fatigue, weight changes, and severe complications if untreated, particularly in individuals with suspected thyroid disorders. Per the 2023 Endocrinology guidelines, the test employs endocrinology with immunoassay technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for thyroid screening in clinical settings. This diagnostic falls under thyroid screening and targets individuals with suspected thyroid dysfunction, addressing the challenge of accurate free thyroid hormone assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: FT3 FT4 Pfl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1980s by endocrinology labs, this test advanced free thyroid hormone screening.**Purpose**: The test screens for 2 parameters including free T3 to guide thyroid assessment, assess free thyroid hormone levels, and inform treatment and prevention strategies.**Test Parameters**: 1. Free T3, 2. Free T4.**Pretest Condition**: No fasting required; patients should report fatigue, weight changes, or recent thyroid symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fatigue, weight changes, prior thyroid reactions, or family history of thyroid disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated thyroid disorders including metabolic issues, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible thyroid disorders, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in endocrinology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: TSH or imaging for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Endocrinology Guidelines 2023, Journal of Endocrinology 2024, Chemistry 2025. |
